News | May 11, 2022
Aurobindo Pharma Ltd gets 6 observations from USFDA for Unit VII
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
The partners also aim to expand their work to Latin America for the first time
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
The plan is to advance innovative therapies to drug-resistant cancers
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
While Pregabalin will be manufactured at the Aurangabad facility, Iloperidone will be manufactured at the Goa facility
Subscribe To Our Newsletter & Stay Updated
